Enhancing Tamoxifen Therapy with α-Mangostin: Synergistic Antiproliferative Effects on Breast Cancer Cells and Potential Reduced Endometrial Impact
-
Published:2023-11-08
Issue:11
Volume:16
Page:1576
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Vargas-Castro Rafael1ORCID, García-Becerra Rocío23ORCID, Díaz Lorenza1ORCID, Avila Euclides1ORCID, Ordaz-Rosado David1, Bernadez-Vallejo Samantha V.1, Cano-Colín Saúl2, Camacho Javier4ORCID, Larrea Fernando1ORCID, García-Quiroz Janice1ORCID
Affiliation:
1. Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de Mexico 14080, Mexico 2. Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico 3. Programa de Investigación de Cáncer de Mama, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico 4. Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del I.P.N., Ciudad de Mexico 07360, Mexico
Abstract
Breast cancer is the most prevalent neoplasia among women worldwide. For the estrogen receptor-positive (ER+) phenotype, tamoxifen is the standard hormonal therapy; however, it carries the risk of promoting endometrial carcinoma. Hence, we aimed to evaluate the antiproliferative effect of the phytochemical α-mangostin (AM) as a co-adjuvant alongside tamoxifen on breast cancer cells to improve its efficacy while reducing its adverse effects on endometrium. For this, ER+ breast cancer cells (MCF-7 and T-47D) and endometrial cells (N30) were treated with AM, 4-hydroxytamoxifen (4-OH-TMX), and their combination. Cell proliferation was evaluated using sulforhodamine B assay, and the pharmacological interaction was determined through the combination index and the dose reduction index calculation. The genes KCNH1, CCDN1, MKI67, and BIRC5 were amplified by real-time PCR as indicators of oncogenesis, cell cycle progression, cell proliferation, and apoptosis, respectively. Additionally, genes involved in ER signaling were analyzed. In breast cancer cells, the combination of AM with 4-OH-TMX showed a synergistic antiproliferative effect and favorable dose reduction. AM and 4-OH-TMX decreased KCNH1, CCND1, and BIRC5 gene expression. In endometrial cells, AM decreased MKI-67 gene expression, while it reverted the 4-OH-TMX-dependent CCND1 upregulation. This study establishes the benefits of incorporating AM as a co-adjuvant for first-line ER+ breast cancer therapy.
Funder
Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference58 articles.
1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023 2. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis;Sotiriou;J. Natl. Cancer Inst.,2006 3. Zattarin, E., Leporati, R., Ligorio, F., Lobefaro, R., Vingiani, A., Pruneri, G., and Vernieri, C. (2020). Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells, 9. 4. Progesterone Receptor Signaling Mechanisms;Grimm;J. Mol. Biol.,2016 5. Tamoxifen: The drug that came in from the cold;Caldas;Br. J. Cancer,2009
|
|